“Unusually Long Survival (More Than Five Years to More Than 31 Years) in Twelve Patients With Relapsed Medulloblastoma Treated With Antineoplastons in Phase II Studies”. European Journal of Clinical Medicine, vol. 6, no. 4, Oct. 2015, pp. 1-8, https://doi.org/10.24018/clinicmed.2025.6.4.389.